IFNL3 rs12970134: Hepatitis C Treatment Response
The rs12970134 single nucleotide polymorphism (SNP) in the IFNL3 gene is a key predictor of treatment success for chronic hepatitis C using interferon-alpha-based therapies. Its prevalence and the associated treatment response vary significantly among different ancestral populations.
What each genotype means
Favorable treatment response
This genotype is associated with a higher likelihood of achieving a sustained virologic response when treated with interferon-alpha-based therapies for hepatitis C. While this variant was a primary predictor for older treatment regimens, modern direct-acting antiviral therapies are often less impacted by this gene. Please discuss your specific treatment options and clinical context with your healthcare provider.
This genotype is most common in individuals of European descent and less frequent in other populations.
Intermediate treatment response
Individuals with this genotype show an intermediate likelihood of responding to interferon-alpha-based hepatitis C treatments compared to those with the CC genotype. Because treatment outcomes depend on many clinical factors, this result should be interpreted by your clinician alongside other health information. Please consult your doctor or pharmacist regarding the most appropriate current therapies for your situation.
This genotype is found at varying frequencies across global populations, often serving as a common intermediate state.
Less favorable treatment response
This genotype is statistically associated with a lower probability of achieving a sustained virologic response when using older interferon-alpha-based hepatitis C regimens. Modern medical guidelines have evolved, and many newer antiviral treatments are not influenced by this genetic variant. You should discuss your clinical history and current treatment options with your healthcare provider to determine the best path forward.
This genotype is more common in certain non-European populations and is generally less frequent than the CC genotype in individuals of European ancestry.
What is the rs12970134 Variant?
rs12970134 is a common genetic variation, specifically a single nucleotide polymorphism (SNP), located in the regulatory region upstream of the Interferon Lambda 3 (*IFNL3*) gene on chromosome 19. This SNP involves a change from the nucleotide Cytosine (C) to Thymine (T) at a specific position in the DNA sequence. While it does not alter the amino acid sequence of the IFNL3 protein, it influences the gene's expression levels, meaning it can affect how much of the interferon lambda 3 protein is produced by the body's cells. This regulatory role is crucial because interferon lambda 3 is a vital component of the immune system's defense against viral infections, particularly in the liver. The specific genotype an individual carries at rs12970134 can therefore impact their immune response and how they react to certain antiviral treatments.
The Role of the IFNL3 Gene
The *IFNL3* gene encodes the interferon lambda 3 protein, a member of the type III interferon family. These proteins are critical signaling molecules that play a significant role in the innate immune response, acting as a first line of defense against viral pathogens. Interferon lambda 3 is particularly important for antiviral immunity in epithelial tissues, including the liver. When the liver is infected with the Hepatitis C virus (HCV), the body's natural production of interferons, including lambda 3, is part of the immune system's attempt to clear the infection. Historically, interferon-alpha therapy was a cornerstone treatment for chronic hepatitis C, aiming to boost this natural antiviral response. The *IFNL3* gene's function is therefore central to understanding why some individuals naturally control viral infections better or respond more effectively to interferon-based treatments than others.
Clinical Associations and Evidence Strength
The association between the rs12970134 variant and the outcome of interferon-alpha-based therapy for chronic hepatitis C is well-established and considered strong. Numerous large-scale clinical studies and meta-analyses have consistently shown that individuals with the CC genotype at rs12970134 have a significantly higher rate of achieving a sustained virologic response (SVR), which is the primary goal of treatment and indicates a cure. Conversely, individuals with the TT genotype are more likely to experience treatment failure. The CT genotype typically shows an intermediate response rate. This strong predictive power led to its consideration in clinical practice guidelines for hepatitis C treatment before the widespread adoption of direct-acting antiviral (DAA) therapies. While DAAs have largely replaced interferon-based treatments, rs12970134 remains a landmark example of pharmacogenomics in action.
Global Population Frequency
The frequency of the rs12970134 genotypes varies considerably across different ancestral populations, which has implications for understanding treatment response patterns globally. The CC genotype, associated with a favorable response to interferon-alpha therapy, is most common in individuals of European and African descent. In contrast, the T allele, and consequently the TT genotype associated with a less favorable response, is found at higher frequencies in populations of East Asian ancestry. These differences in allele frequencies mean that the proportion of individuals likely to benefit from older interferon-based treatments differed across ethnic groups. Examining data from large population databases like gnomAD provides detailed insights into these variations, highlighting the importance of considering genetic diversity when interpreting research findings and clinical outcomes.
What Your Results Mean
Understanding your genotype at rs12970134 can provide insight into historical treatment responses for hepatitis C, but it is not a diagnostic tool for the disease itself. If you have this genetic information, it is best discussed with a healthcare professional, such as your doctor or a genetic counselor. They can help you interpret what this variant means in the context of your personal health history and the most current treatment options available, which for hepatitis C are now predominantly direct-acting antivirals. It is crucial to remember that genetic information should not be used to make independent medical decisions or to alter medication plans. Always consult with a qualified healthcare provider for any health-related questions or treatment adjustments.
How common is this variant?
The frequency of the rs12970134 genotypes varies significantly by ancestry. The favorable CC genotype is most common in individuals of European and African descent, while the T allele is more frequent in East Asian populations.
Frequently asked questions
Does rs12970134 predict my risk of getting Hepatitis C?
No, the rs12970134 variant does not influence your susceptibility to contracting the Hepatitis C virus. Its primary known association is with the effectiveness of specific antiviral treatments.
Is this SNP still relevant for current Hepatitis C treatments?
The clinical relevance of rs12970134 has diminished with the advent of direct-acting antiviral (DAA) therapies, which are now the standard of care and do not rely on interferon. However, it remains historically significant and may be relevant if interferon-based therapy is considered.
Can I get tested for rs12970134?
Genetic testing for rs12970134 is available through various direct-to-consumer genetic testing services and clinical laboratories. However, its utility in guiding current medical decisions should be discussed with a healthcare provider.
Does this variant affect other types of infections?
While interferon lambda proteins are involved in responses to various viral infections, the strongest and most clinically validated association for rs12970134 is with the response to interferon-alpha therapy in chronic hepatitis C patients.
Sources & further reading
Educational information only, last refreshed 9/25/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs12970134?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in IFNL3
A genetic marker near IFNL3/IFNL4 associated with spontaneous hepatitis C clearance and response to interferon-based therapies, though its predictive power is often secondary to IFNL4 variants like rs368234815.
Upstream variant near IFNL3 associated with spontaneous clearance of hepatitis C virus infection and hepatic inflammatory responses.